Regulatory milestones

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $12.74 (21%) to $72.83 last week after at least two analysts raised their price targets on the stock and EMA's CHMP backed approval of an MAA for Lojuxta lomitapide. Canaccord's Salveen Richter and JPMorgan's Cory Kasimov cited progress with the launch of lomitapide for homozygous familial hypercholesterolemia (hoFH) in the U.S., where it is marketed as Juxtapid (see Analysts, A20).